Statin-related adverse events only observed in unblinded and not in blinded trials; a nocebo effect?

9-5-2017 • Gupta A, The Lancet, 2017
In the ASCOT-LLA trial, adverse events, such as muscle pain, were more common with atorvastatin treatment in the unblinded phase, but not in de blinded phase of the trial.  Read more

At young age, classic risk factors related to recurrent cardiovascular events

3-5-2017 • Van de Berg MJ, et al, J Am Cardiol 2017
Smoking, blood pressure and lipid levels increase risk of recurrent cardiovascular events in young patients or within a short time span in patients of the Dutch SMART cohort.  Read more
News • 2-5-2017

Grand Debate at ESC Heart Failure on Sacubitril/Valsartan: is it ready to be used as first-line therapy?

ESC HF 2017 Summary of this new session type, in which Prof John McMurray and Dr. Mariell Jessup debated why or why not ARNI should be considered first-line therapy in patients with heart failure. Read more
News • 1-5-2017

HF patients in sinus rhythm, but not with AF, benefit from reducing heart rate

ESC HF 2017 Pooled individual patient data reveal that slowing heart rate with a betablocker lowers mortality in sinus rhythm, while in AF patients baseline or attained heart rate does not affect mortality. Read more
News • 1-5-2017

HFpEF patients do not benefit from heart rate reduction

ESC HF 2017 In EDIFY, treatment with ivabradine for 8 months reduced heart rate, but did not improve E/e’, exercise capacity or NT-proBNP levels in patients with HFpEF. Read more

Limited discriminative power ACC/AHA criteria in identifying very high-risk CVD patients

24-4-2017 • van den Berg MJ, Eur Heart J, 2017
Single very high-risk factors or simple criteria, such as the ACC/AHA very high-risk criteria, have limited discriminative power to identify patients at highest risk of recurrent MACE.  Read more

Risk of stroke and dementia increased by artificially sweetened beverages

4-5-2017 • Pase MP, et al, Stroke 2017
Artificially sweetened soft drink consumption was associated with an increased 10-year risk of stroke and dementia in prospective data from the Framingham Offspring Cohort.  Read more

Incidence atrial fibrillation increased over last decade, which is expected to continue

3-5-2017 • Lane DA, et al, J Am Heart Assoc. 2017
Using a primary care population, it was observed that the incidence of AF increased in patients >75 yrs during the last decade, whereas mortality in these patients did not decrease as it did in younger patients.  Read more
News • 1-5-2017

Risk of worsening HF accurately identified with multisensory telemonitoring device

ESC HF 2017 Based on heart sounds, respiration rate, and volume, thoracic impedance, night heart rate, and daily activity HeartLogic predicts the risk of an HF event independent of baseline variables. Read more
News • 1-5-2017

New HF category with midrange EF resembles HFrEF, albeit with better outcomes

ESC HF 2017 Analysis of CHARM data revealed that outcomes improve with increasing EF up to ~50%, and that candesartan is effective in HFrEF and HFmrEF, but not in HFpEF. Read more

Prevention of acute decompensated HF by intensive BP-lowering

24-4-2017 • Upadhya B, et al, Circ Heart Fail.
In the SPRINT trial, targeting an SBP of <120 mmHg, as compared with <140 mmHg, significantly reduced the risk of developing ADHF by 36% in all predetermined subgroups.  Read more
News • 24-4-2017

LDL is causal factor in ASCVD - states EAS Consensus Panel

A Consensus Panel of the European Atherosclerosis Society (EAS) published a statement that shows that the total evidence on LDL-lowering fulfils the criteria for a causal role of LDL-c in atherosclerotic vascular disease. Read more

Upcoming meetings

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...